Skip to main content

Immunology

    Rheumatology Round-Up with Drs. Kavanaugh & Cush

    The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

    RT @SituationRheum: 📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future

    👉close surveillance ➡️ early det
    3 years 3 months ago
    📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI
    RT @uptoTate: "The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan
    3 years 3 months ago
    "The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow
    RT @RADoctor: Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 2
    3 years 3 months ago
    Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
    RT @AdamJBrownMD: Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically dive
    3 years 3 months ago
    Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP
    What's New in Calcium Pyrophosphate Disease? with Dr. Michael Pillinger

    NYU's Dr. Pillinger talks about Dr. Ann Rosenthal's state of the art talk on calcium pyrophosphate disease at ACR 2020.

    RT @DrMiniDey: Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis pati
    3 years 3 months ago
    Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD
    RT @drdavidliew: Just a reminder:
    inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhi
    3 years 3 months ago
    Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
    RT @RichardPAConway: Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients tre
    3 years 3 months ago
    Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
    RT @RichardPAConway: Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons
    3 years 3 months ago
    Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm